EUROEYES (01846) plans to invest heavily in the acquisition of the leading Dutch refractive surgery company FYEO Europe B.V. Trading is set to resume on February 27th.

EuroEyes (01846) announced that on February 20, 2026 (after trading hours), its wholly-owned subsidiary EuroEyes Netherlands intends to acquire all the issued share capital of FYEO Europe B.V. from Committed Capital, STAK Batoan, Mateflo, FYEO WPP, and STAK FYEO, with the total consideration calculated based on the equity value plus locked box compensation minus any leakage amount. Assuming (a) completion will be finalized on July 15, 2026; and (b) the leakage amount is zero, the estimated maximum consideration will be approximately 145.8 million euros (equivalent to approximately 1.234 billion Hong Kong dollars). The company has applied to the Stock Exchange for the resumption of trading of its shares on the Stock Exchange starting from 9:00 am on February 27, 2026. The target company is primarily engaged in refractive eye surgery through laser treatment or intraocular lens implantation. The target group is the leading private refractive eye surgery platform in the Dutch market, specializing in providing intraocular lens implantation and laser ophthalmic procedures, including refractive lens exchange (RLE), intraocular lens implantation (IL), femtosecond laser surgery, Intralasik, TransPRK, and Lasek surgeries. Given the target group's leading position in the rapidly growing Dutch market, the Board considers the acquisition to be a strategic fit for the Group. This is because both the company and the target group are pure players in refractive eye surgery, with a focus on patient-centered care. The Board recognizes that the acquisition will enhance the Group's market position, improve overall competitiveness, ensure long-term sustainable development, and create value for the company and its shareholders, considering the target group's readiness to continue its growth trajectory with several favorable growth levers, including but not limited to the increasing direct-to-end consumer market reach and technological advancements in refractive eye surgery.